Lecithin-Cholesterol Acyltransferase (LCAT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Lecithin-cholesterol acyltransferase (LCAT) deficiency is an autosomal recessive disorder characterized by notably low high-density lipoprotein (HDL) cholesterol levels. This phenotype is less severe compared to individuals with total LCAT deficiency. The observed distinctions between LCAT deficiency and fisheye disease are attributed to mutations in the LCAT gene. These mutations determine whether the gene encodes variants that fail to esterify HDL cholesterol and apoB-containing lipoproteins (leading to LCAT deficiency) or exclusively affect HDL. Clinical features of this disorder include corneal opacities, splenomegaly, normocytic normochromic anemia, low levels of HDL and α-lipoproteins, and elevated LDL levels. Fisheye disease can also manifest without anemia, splenomegaly, or renal complications. Likely, the accumulation of cholesterol-rich multilamellar particles, known as lipoprotein-X, in the plasma plays a role in the kidney's pathogenesis. Renal manifestations primarily involve proteinuria, including nephrotic syndrome, progressive renal failure, and hypertension. On light microscopy, observations include intimal hyperplasia, foam cell presence in glomeruli, and thickening of the glomerular basement membrane (GBM) with effacement of the foot processes.

·       The global prevalence of Lecithin-cholesterol acyltransferase (LCAT) deficiency ranges from 0.75 to 1.15 per million cases.

 

Thelansis’s “Lecithin-Cholesterol Acyltransferase (LCAT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Lecithin-Cholesterol Acyltransferase (LCAT) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Lecithin-Cholesterol Acyltransferase (LCAT) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Lecithin-Cholesterol Acyltransferase (LCAT) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Lecithin-Cholesterol Acyltransferase (LCAT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Lecithin-Cholesterol Acyltransferase (LCAT), Lecithin-Cholesterol Acyltransferase (LCAT) market outlook, Lecithin-Cholesterol Acyltransferase (LCAT) competitive landscape, Lecithin-Cholesterol Acyltransferase (LCAT) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)